DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Trimmed by MetLife Investment Management LLC

MetLife Investment Management LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 120,567 shares of the medical device company’s stock after selling 1,844 shares during the quarter. MetLife Investment Management LLC’s holdings in DexCom were worth $9,376,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Geode Capital Management LLC raised its position in shares of DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock worth $775,256,000 after buying an additional 56,094 shares in the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after acquiring an additional 710,858 shares during the period. Norges Bank bought a new stake in DexCom during the fourth quarter worth approximately $385,367,000. Charles Schwab Investment Management Inc. lifted its position in DexCom by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after purchasing an additional 91,051 shares during the period. Finally, Artisan Partners Limited Partnership boosted its stake in DexCom by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company’s stock valued at $144,152,000 after purchasing an additional 201,181 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DXCM. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price objective for the company. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Finally, Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

DexCom Stock Down 3.6 %

DexCom stock opened at $66.11 on Tuesday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $25.92 billion, a PE ratio of 46.23, a P/E/G ratio of 2.30 and a beta of 1.50. The firm’s 50 day moving average price is $74.62 and its two-hundred day moving average price is $76.74.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last three months. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.